SVAS BIOSANA risk profile

32 Normal where most of the sector sits

Measured 1 September 2026 from SVS.MI's filed statements. Recomputed nightly.

32 (Normal), driven by Cash conversion at 76, over 5 weighted categories on the MANUFACTURER profile.

What is measured

MechanismReadingBandDirectionDriver
Market expectation44ElevatedStableOne-year price volatility — 27.9%
Operating pressure39NormalWorseningCosts outgrowing revenue — -0.7 percentage points
Cash conversion76StretchedWorseningCapital spending against operating cash — 1.89x
Leverage and coverage42ElevatedWorseningInterest cover — 4.62x
Competitive position11ContainedStableRevenue-growth gap against peers — +27.2 percentage points
ConcentrationReads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company.

These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.

Healthcare companies with a risk reading

Financials, valuation and price history for SVAS BIOSANA